ArticleHaematologica2019
Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells.
Open access · goldAbstract read
In one paragraph
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Navigating the Landscape of Exosomal microRNAs: Charting Their Pivotal Role as Biomarkers in Hematological Malignancies.Non-coding RNA · 2025Review
- E2F1 Facilitates the Proliferation and Stemness of Gastric Cancer Cells by Activating CDC25B Transcription and Modulating the MAPK Pathway.Biochemical genetics · 2025Article
- Androgen receptor inhibition sensitizes glioblastoma stem cells to temozolomide by the miR-1/miR-26a-1/miR-487b signature mediated WT1 and FOXA1 silencing.Cell death discovery · 2025Article
- Benchmarking miRNA reference genes in B-cell precursor acute lymphoblastic leukemia.Scientific reports · 2024Article
- Circulating Exosomes from Septic Mice Activate NF-κB/MIR17HG Pathway in Macrophages.Biomedicines · 2024Article
- Chromatographic analysis of ponatinib and its impurities: method development, validation, and identification of new degradation product.Frontiers in chemistry · 2024Article
- A diagnostic circulating miRNA signature as orchestrator of cell invasion via TKS4/TKS5/EFHD2 modulation in human gliomas.Journal of experimental & clinical cancer research : CR · 2023Article
- Intricate crosstalk between MYB and noncoding RNAs in cancer.Cancer cell international · 2021Review
- MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate.International journal of molecular sciences · 2021Article
- MiR-17-92 enriched exosomes derived from multipotent mesenchymal stromal cells enhance axon-myelin remodeling and motor electrophysiological recovery after stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Regulation of MYB by distal enhancer elements in human myeloid leukemia.Cell death & disease · 2021Article
- The transcription factor TAL1 and miR-17-92 create a regulatory loop in hematopoiesis.Scientific reports · 2020Article
- Comparison of microRNA Expression Profile in Chronic Myeloid Leukemia Patients Newly Diagnosed and Treated by Allogeneic Hematopoietic Stem Cell Transplantation.Frontiers in oncology · 2020Article
- Inflexibility of the plasma miRNA response following a high-carbohydrate meal in overweight insulin-resistant women.Genes & nutrition · 2020Article
- The Wnt/β-Catenin/LEF1 Pathway Promotes Cell Proliferation at Least in Part Through Direct Upregulation of miR-17-92 Cluster.Frontiers in genetics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Manuela SpagnuoloDepartment of Research, Advanced Diagnostics and Technological Innovation, Oncogenomic and Epigenetic Unit, Translational Research Area, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Giulia RegazzoDepartment of Research, Advanced Diagnostics and Technological Innovation, Oncogenomic and Epigenetic Unit, Translational Research Area, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Marco De DominiciDepartment of Cancer Biology and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Andrea SacconiDepartment of Research, Advanced Diagnostics and Technological Innovation, Oncogenomic and Epigenetic Unit, Translational Research Area, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Andrea PelosiDepartment of Research, Advanced Diagnostics and Technological Innovation, Oncogenomic and Epigenetic Unit, Translational Research Area, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Etleva KoritaDepartment of Research, Advanced Diagnostics and Technological Innovation, Oncogenomic and Epigenetic Unit, Translational Research Area, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Francesco MarchesiDepartment of Clinical and Experimental Oncology-Hematology and Stem Cell Transplant Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Francesco PisaniDepartment of Clinical and Experimental Oncology-Hematology and Stem Cell Transplant Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Alessandra MagentaIstituto Dermopatico dell'Immacolata-IRCCS, FLMM, Laboratorio di Patologia Vascolare, Rome, Italy.
Valentina LulliDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Iole CordoneDepartment of Research, Advanced Diagnostics and Technological Innovation, Clinical Pathology Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Andrea MengarelliDepartment of Clinical and Experimental Oncology-Hematology and Stem Cell Transplant Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Sabrina StranoDepartment of Research, Advanced Diagnostics and Technological Innovation, Oncogenomic and Epigenetic Unit, Translational Research Area, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Giovanni BlandinoDepartment of Research, Advanced Diagnostics and Technological Innovation, Oncogenomic and Epigenetic Unit, Translational Research Area, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Maria G RizzoDepartment of Research, Advanced Diagnostics and Technological Innovation, Oncogenomic and Epigenetic Unit, Translational Research Area, IRCCS - Regina Elena National Cancer Institute, Rome, Italy maria.rizzo@ifo.gov.it bruno.calabretta@jefferson.edu.
Bruno CalabrettaDepartment of Cancer Biology and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA maria.rizzo@ifo.gov.it bruno.calabretta@jefferson.edu.
Istituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Superiore di Sanità · ITSidney Kimmel Cancer Center · USThomas Jefferson University · US
Funding
Targeting the C/EBPalpha-Gfi-pathway in CML stem cellsR01CA167169 · NCI · THOMAS JEFFERSON UNIVERSITY · PI CALABRETTA, BRUNO · 2013 to 2017
$1.6MNCI NIH HHS R01 CA167169
Abstract
MicroRNAs, non-coding regulators of gene expression, are likely to function as important downstream effectors of many transcription factors including MYB. Optimal levels of MYB are required for transformation/maintenance of
Indexed as
Gene Expression Regulation, LeukemicMultigene FamilyTranscriptional ActivationAnimalsBlast CrisisHumansK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMiceMice, Inbred NODMice, SCIDMicroRNAsProto-Oncogene Proteins c-mybRNA, NeoplasmXenograft Model Antitumor AssaysMicroRNAsMIRN17 microRNA, humanMYB protein, humanProto-Oncogene Proteins c-mybRNA, Neoplasm
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.